New hope for pancreatic cancer: targeted drug trial launches
NCT ID NCT07491445
First seen Mar 24, 2026 · Last updated Apr 29, 2026 · Updated 6 times
Summary
This phase 3 trial tests a new drug called daraxonrasib, alone or with standard chemotherapy, for people with metastatic pancreatic cancer that has spread. About 900 adults with a specific RAS gene mutation will be randomly assigned to one of three treatment groups. The study aims to see if the new drug helps people live longer or slows cancer growth compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Comprehensive Cancer Centers of Nevada
RECRUITINGHenderson, Nevada, 89052, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taylor Cancer Research Center
RECRUITINGMaumee, Ohio, 43537, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.